Table 1.

Demographics of the cetuximab-treated patients with HNSCC in this study

RegimenPatients, nTumor site (patients)Mean age, yMaleFemale
UPCI 08-013a18OC (8)59.7126
OP (8)
L (2)
UPCI 05-003b22OC (6)60.0139
OP (7)
L (3)
HP (3)
Other (3)

Abbreviations: HP, hypopharynx; L, larynx; OC, oral cavity; OP, oropharynx.

  • aCetuximab 250 mg/m2 weekly (after an initial dose of 400 mg/m2).

  • bCetuximab 250 mg/m2 days weekly (after an initial dose of 400 mg/m2), docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, repeated every 21 days–3 cycles, then radiotherapy to 70 Gy (2 Gy/d) with concurrent cetuximab 250 mg/m2 weekly cisplatin 30 mg/m2, then maintenance cetuximab for 6 months. Blood was drawn during single-agent cetuximab maintenance.